development of treatments for amyloidosis, amyloid-related diseases, and C-reactive protein-driven disease mechanisms
Pentraxin Therapeutics' position looks highly stable across these two snapshots. In January 2014, it described itself as building treatments for systemic amyloidosis and other amyloid-related diseases, explicitly including Alzheimer's disease and type II diabetes, while also targeting disease mechanisms driven by C-reactive protein in cardiovascular and inflammatory conditions. In January 2015, that core claim stayed intact.
What changed is mostly framing, not direction. The 2015 version adds more company-origin detail, saying the business was built around Professor Sir Mark Pepys's research intellectual property and proprietary knowledge. That gives the story a clearer scientific ownership line, but it does not materially change the therapeutic thesis.
So the belief evolution here is minimal: same disease areas, same mechanistic emphasis, same broad ambition. Evidence is thin because we only have two Wayback snapshots, about a year apart, and both read like closely related corporate descriptions rather than a real shift in strategy. Based on this record, the company refined its self-description more than it changed its beliefs.
1 changes · divergence 0.08
amyloidosis, amyloid-related diseases, and C-reactive protein-targeted therapeutics2012-08-26
Pentraxin Therapeutics presents itself as a UCL spinout built around Professor Mark Pepys's research, focused on developing new treatments for systemic amyloidosis and other amyloid-related diseases, including Alzheimer's disease and type II diabetes, while also targeting what it describes as the pathogenic effects of C-reactive protein in cardiovascular and inflammatory diseases.
SourceDeveloping treatments for systemic amyloidosis, amyloid-related diseases, and C-reactive protein-driven disease2017-05-20
Pentraxin Therapeutics states that it exists to develop new treatments based on intellectual property and proprietary knowledge from Professor Sir Mark Pepys's research group, focusing on systemic amyloidosis, amyloid-related diseases such as Alzheimer's disease and type II diabetes, and the pathogenic effects of C-reactive protein in cardiovascular and inflammatory diseases.
Sourcedevelopment of treatments for amyloidosis, amyloid-related diseases, and C-reactive protein-driven disease mechanisms2014-01-11
Pentraxin Therapeutics states that it is focused on creating new treatments for systemic amyloidosis and other amyloid-related diseases, including Alzheimer's disease and type II diabetes, and also on targeting the pathogenic effects of C-reactive protein in cardiovascular and inflammatory diseases. The snapshot presents these disease areas as the company's core scientific and therapeutic focus.
Sourcedevelopment of treatments for amyloidosis, amyloid-related diseases, and C-reactive protein-driven disease mechanisms2015-01-06
Pentraxin Therapeutics stated that it was built around Professor Sir Mark Pepys's research intellectual property and proprietary knowledge, and that it designs new treatments for systemic amyloidosis, amyloid-related diseases including Alzheimer's disease and type II diabetes, and diseases driven by the pathogenic effects of C-reactive protein in cardiovascular and inflammatory conditions.
Sourcedevelopment of treatments for amyloidosis, amyloid-related diseases, and C-reactive protein-mediated disease2018-03-24
Pentraxin Therapeutics states that its proprietary research and intellectual property support the design of new treatments for systemic amyloidosis, amyloid-related diseases such as Alzheimer's disease and type II diabetes, and diseases driven by the pathogenic effects of C-reactive protein, with development advanced through UCL-based research and major pharmaceutical collaboration.
SourcePentraxin Therapeutics mission and disease-targeting strategy2013-06-15
Pentraxin Therapeutics states that it exists to develop new treatments based on Professor Mark Pepys's research, focusing on systemic amyloidosis, amyloid-related diseases including Alzheimer's disease and type II diabetes, and the pathogenic effects of C-reactive protein in cardiovascular and inflammatory diseases. The company presents its work as translating proprietary academic research and intellectual property from UCL into therapeutics through internal development and collaboration with GlaxoSmithKline.
Sourcetherapeutic development for systemic amyloidosis, amyloid-related diseases, and C-reactive protein-driven disease2016-01-10
Pentraxin Therapeutics states that it is focused on turning Sir Mark Pepys's research into new treatments for systemic amyloidosis and other amyloid-related diseases, including Alzheimer's disease and type II diabetes, while also targeting what it describes as the pathogenic effects of C-reactive protein in cardiovascular and inflammatory diseases. The company presents these disease areas as tractable targets for drug discovery and emphasizes development through UCL-based research support and collaboration with GlaxoSmithKline.
Sourcetherapeutics for amyloidosis, amyloid-related diseases, and C-reactive protein-driven pathology2011-09-26
Pentraxin Therapeutics states that it develops new treatments based on intellectual property and proprietary knowledge from Professor Mark Pepys's research group, focusing on systemic amyloidosis, amyloid-related diseases including Alzheimer's disease and type II diabetes, and on reducing the pathogenic effects of C-reactive protein in cardiovascular and inflammatory diseases.
Source